May 13th - 18th 2022, San Francisco, CA
Visit us at booth 1908 to learn about our genomic diagnostic tests for interstitial lung disease and lung cancer. Join our Industry Theaters:
May 17th, 12:30-1:00pm – Integrating Novel Genomic Data to Improve ILD Diagnostic and Prognostic Confidence
May 17th, 1:30-2:00pm – Integrating the Percepta Genomic Sequencing Classifier for lung nodule risk stratification
View our on-demand webinar
Hear how Dr. Kurman uses Percepta GSC to stratify the risk of primary lung cancer across all pre-test risk groups as a guide for patient management when bronchoscopy is inconclusive.
June 3rd-7th | Chicago, IL
Be sure to stop by booth #21085 to learn more about Veracyte’s portfolio of oncology products inclusive of lung cancer
Envisia detects genomic UIP pattern to improve ILD diagnostic and prognostic confidence.
Percepta GSC stratifies the risk of lung cancer to guide patient management for when bronchoscopy is inconclusive.
PIPELINE
Percepta Nasal Swab brings genomic objectivity to lung nodule risk assessment with a simple, non-invasive tool.
PIPELINE
Percepta Genomic Atlas guides personalized treatment earlier in lung cancer diagnosis.
Transform uncertainty into confidence
Veracyte offers a suite of actionable genomic tests that can offer greater confidence and clarity at every step of your lung cancer and interstitial lung disease patient management.